AI Consultant · Minneapolis, MN

Hire an AI consultant in Minneapolis.

Target and Best Buy have full internal AI strategy teams. Their suppliers and mid-market ecosystem companies generally do not. A $150M Minnesota retailer or distributor can justify a short, fixed-scope engagement to test whether ongoing AI investment is warranted. That is harder to justify than a $150,000 annual hire for a function the company is not sure it needs long-term.

UnitedHealth Group vendors face data governance requirements that most AI consultants have not read. Mayo Clinic's healthcare AI needs require someone who knows how clinical AI interacts with FDA guidance, not someone who knows AI in general. The difference matters when you are building something.

Fixed-scope engagement. Five to eight weeks. Written deliverables yours to keep.

How we work

Tell us about your AI investment decision.

The mid-market strategy gap in Minneapolis.

Large Minneapolis enterprises -- Cargill, 3M, US Bancorp -- have dedicated AI teams and internal capacity to evaluate vendors. They do not need an independent consultant for basic AI strategy. The gap is in the mid-market: distributors, agricultural tech companies, and regional retailers with $50M to $500M in revenue who need a clear-eyed assessment before committing capital.

The question a $200M distributor actually needs answered is not "should we use AI" but "which of these three use cases would generate a return, and which ones are vendor hype." That requires someone who has worked through the analysis before, not a vendor with a product to sell.

Mid-market companies in Minnesota's agricultural and manufacturing sectors have data assets -- ten years of yield data, machine sensor logs, procurement histories -- that create real AI advantages. Most of them have not mapped those assets to specific AI use cases. That mapping is often the most valuable thing a three-month engagement produces.

The consulting deliverable includes a prioritized use case analysis, a realistic cost-benefit estimate for the top two or three use cases, and an honest assessment of which ones are not worth pursuing at your current data maturity.

Retail AI: right-sizing the investment.

Target and Best Buy compete on AI in areas that require massive infrastructure: personalization at scale, real-time inventory optimization across thousands of stores, and supply chain forecasting with hundreds of supplier variables. A regional retailer competing in those areas is outgunned before they start.

The right AI investments for a mid-size Minnesota retailer are narrower. Demand forecasting for a regional SKU set using proprietary historical data. Contract analysis and supplier performance scoring. Internal document retrieval to reduce time spent on compliance and vendor management. These are tractable with a realistic budget and do not require competing with enterprise-scale AI programs.

The common mistake is deciding to invest in AI in general rather than deciding to invest in a specific use case with a measurable outcome. A $50,000 AI project with a clear ROI hypothesis is worth doing. A $50,000 AI project to "explore AI opportunities" rarely produces anything that justifies the spend.

Healthcare ecosystem: UHG and Mayo constraints.

UHG vendor data governance goes beyond HIPAA

UnitedHealth Group's vendor agreements include AI-specific data use restrictions that most vendors discover during procurement, not before. If you are building a product that processes UHG member data, the AI data governance questions need legal review before development begins.

Fine-tuning on de-identified member data requires written permission

De-identification under HIPAA Safe Harbor removes the obvious identifiers, but UHG's vendor agreements typically restrict model training on de-identified member data without separate authorization. This is a contract question, not just a HIPAA question.

Mayo Clinic clinical AI requires FDA pathway analysis

AI tools used in clinical workflows at Mayo Clinic or in the Rochester healthcare ecosystem may qualify as Software as a Medical Device under FDA guidance. That classification analysis should happen before any development contract is signed.

The compliance deliverable protects the project

An engagement covering the UHG or Mayo compliance landscape produces a written analysis you can show your legal team, your customer's procurement team, and your investors. It is a reusable asset, not a one-time conversation.

How we work.

1
Discovery call
One hour. We map your data assets, your AI questions, and any existing compliance constraints -- UHG vendor status, FDA-adjacent use cases, or data governance gaps. We scope the engagement and give you a fixed price.
2
Structured interviews
Sessions with business, IT, and a relevant domain owner -- a VP of Merchandising for retail use cases, a clinical informatics lead for healthcare. We build the use case list from what your team knows, not from a generic template.
3
Analysis and drafting
Use case prioritization with ROI estimates, compliance risk assessment for any regulated use cases, vendor due diligence checklist, and a 90-day implementation roadmap for the highest-priority use case. Draft delivered for your review.
4
Review and handoff
Final session to walk through findings. All deliverables are yours to share with your board, investors, or implementation team. No retainer, no ongoing obligation.

Questions about AI consulting in Minneapolis.

What does a UHG vendor need to know about AI data governance before building a product that processes UHG member data?: UnitedHealth Group requires vendors accessing member data to comply with both HIPAA and UHG's own vendor data governance standards, which go beyond HIPAA minimums. Specifically: UHG's vendor agreement typically restricts the use of de-identified member data for model training without explicit written permission. This means a vendor who wants to fine-tune an AI model on UHG member data -- even after de-identification -- needs contractual authorization, not just a signed BAA. The de-identification standard UHG uses is the Safe Harbor method under 45 CFR 164.514(b), which has specific technical requirements. If your product logs member interactions and you plan to use those logs to improve a model, that is a data use question that needs legal review before development. UHG's technology contracting team has reviewed AI products before. They will ask these questions during procurement.
How do you evaluate AI use cases for a mid-size Minneapolis retailer -- what distinguishes high-value from low-value projects?: High-value retail AI use cases share two characteristics: the company has proprietary data that gives an advantage a generic AI tool cannot replicate, and the cost of a wrong decision in the use case is measurable. Demand forecasting for a regional distributor with ten years of SKU-level sales data falls into this category. The company's own historical data creates an edge over a generic forecasting API, and forecast errors translate directly to inventory carrying costs or stockouts. Low-value use cases typically involve deploying a generic AI tool -- a customer service chatbot built on a foundation model with no proprietary training data -- in a role where the tool's limitations are hidden until a customer interaction goes wrong. For a $150M Minnesota retailer, the three use cases worth evaluating are: (1) inventory and demand forecasting using proprietary purchase data, (2) supplier risk scoring using procurement history, and (3) internal document retrieval and contract analysis. Each has a clear data advantage and a measurable outcome.
For a Minneapolis healthcare company, what is the practical distinction between AI tools that require FDA clearance and ones that do not?: FDA's Software as a Medical Device definition turns on whether the AI tool is intended to diagnose, treat, prevent, or mitigate a disease or condition in an identifiable patient. A scheduling optimization tool that decides which patients to call for a preventive screening is administrative and typically does not qualify as SaMD. An AI tool that analyzes a patient's lab values and outputs a clinical recommendation a physician acts on is more likely to qualify. The line is not always clear. FDA's non-binding guidance on clinical decision support software provides a four-question framework. The most important question is whether a healthcare professional could independently verify the basis for the AI output using their own clinical knowledge. If the answer is no -- because the model is a black box -- FDA is more likely to treat the tool as a device. For a Minneapolis healthcare company assessing a vendor's AI clinical tool, the first question to ask is whether the vendor has a De Novo authorization or 510(k) clearance on file. If they do not, ask for a written regulatory classification opinion from their regulatory counsel.
What is the minimum viable AI governance structure for a $200M company making its first significant AI investment?: Four things: an AI use case inventory, a data governance policy that covers training data sourcing and model output review, a vendor review checklist applied before any AI tool touches customer or patient data, and a designated decision-maker who approves AI deployments before they go to production. None of these require a separate AI governance team. The use case inventory is a spreadsheet maintained by the IT or product owner. The data governance policy is a two-page document reviewed by legal. The vendor checklist covers BAA status (if applicable), subprocessor list, and data retention terms. The designated approver is usually a CTO or VP Engineering with a defined approval threshold -- say, any AI tool that accesses production data requires their sign-off. A $200M company that has these four things in place before their first AI deployment will avoid the three most common and expensive mistakes: deploying a tool that creates compliance exposure, using customer data for model training without contractual authority, and having no record of what AI tools are running in production.

Ready to work through your AI investment decision?

Hire an AI consultant in Minneapolis.

Fixed-scope engagement. Five to eight weeks. Written deliverables yours to keep.

The mid-market strategy gap in Minneapolis.

Retail AI: right-sizing the investment.

Healthcare ecosystem: UHG and Mayo constraints.

UHG vendor data governance goes beyond HIPAA

Fine-tuning on de-identified member data requires written permission

Mayo Clinic clinical AI requires FDA pathway analysis

The compliance deliverable protects the project

How we work.

Discovery call

One hour. We map your data assets, your AI questions, and any existing compliance constraints -- UHG vendor status, FDA-adjacent use cases, or data governance gaps. We scope the engagement and give you a fixed price.

Structured interviews

Sessions with business, IT, and a relevant domain owner -- a VP of Merchandising for retail use cases, a clinical informatics lead for healthcare. We build the use case list from what your team knows, not from a generic template.

Analysis and drafting

Use case prioritization with ROI estimates, compliance risk assessment for any regulated use cases, vendor due diligence checklist, and a 90-day implementation roadmap for the highest-priority use case. Draft delivered for your review.

Review and handoff

Final session to walk through findings. All deliverables are yours to share with your board, investors, or implementation team. No retainer, no ongoing obligation.

Questions about AI consulting in Minneapolis.

What does a UHG vendor need to know about AI data governance before building a product that processes UHG member data?

UnitedHealth Group requires vendors accessing member data to comply with both HIPAA and UHG's own vendor data governance standards, which go beyond HIPAA minimums. Specifically: UHG's vendor agreement typically restricts the use of de-identified member data for model training without explicit written permission. This means a vendor who wants to fine-tune an AI model on UHG member data -- even after de-identification -- needs contractual authorization, not just a signed BAA. The de-identification standard UHG uses is the Safe Harbor method under 45 CFR 164.514(b), which has specific technical requirements. If your product logs member interactions and you plan to use those logs to improve a model, that is a data use question that needs legal review before development. UHG's technology contracting team has reviewed AI products before. They will ask these questions during procurement.

How do you evaluate AI use cases for a mid-size Minneapolis retailer -- what distinguishes high-value from low-value projects?

High-value retail AI use cases share two characteristics: the company has proprietary data that gives an advantage a generic AI tool cannot replicate, and the cost of a wrong decision in the use case is measurable. Demand forecasting for a regional distributor with ten years of SKU-level sales data falls into this category. The company's own historical data creates an edge over a generic forecasting API, and forecast errors translate directly to inventory carrying costs or stockouts. Low-value use cases typically involve deploying a generic AI tool -- a customer service chatbot built on a foundation model with no proprietary training data -- in a role where the tool's limitations are hidden until a customer interaction goes wrong. For a $150M Minnesota retailer, the three use cases worth evaluating are: (1) inventory and demand forecasting using proprietary purchase data, (2) supplier risk scoring using procurement history, and (3) internal document retrieval and contract analysis. Each has a clear data advantage and a measurable outcome.

For a Minneapolis healthcare company, what is the practical distinction between AI tools that require FDA clearance and ones that do not?

FDA's Software as a Medical Device definition turns on whether the AI tool is intended to diagnose, treat, prevent, or mitigate a disease or condition in an identifiable patient. A scheduling optimization tool that decides which patients to call for a preventive screening is administrative and typically does not qualify as SaMD. An AI tool that analyzes a patient's lab values and outputs a clinical recommendation a physician acts on is more likely to qualify. The line is not always clear. FDA's non-binding guidance on clinical decision support software provides a four-question framework. The most important question is whether a healthcare professional could independently verify the basis for the AI output using their own clinical knowledge. If the answer is no -- because the model is a black box -- FDA is more likely to treat the tool as a device. For a Minneapolis healthcare company assessing a vendor's AI clinical tool, the first question to ask is whether the vendor has a De Novo authorization or 510(k) clearance on file. If they do not, ask for a written regulatory classification opinion from their regulatory counsel.

What is the minimum viable AI governance structure for a $200M company making its first significant AI investment?

Four things: an AI use case inventory, a data governance policy that covers training data sourcing and model output review, a vendor review checklist applied before any AI tool touches customer or patient data, and a designated decision-maker who approves AI deployments before they go to production. None of these require a separate AI governance team. The use case inventory is a spreadsheet maintained by the IT or product owner. The data governance policy is a two-page document reviewed by legal. The vendor checklist covers BAA status (if applicable), subprocessor list, and data retention terms. The designated approver is usually a CTO or VP Engineering with a defined approval threshold -- say, any AI tool that accesses production data requires their sign-off. A $200M company that has these four things in place before their first AI deployment will avoid the three most common and expensive mistakes: deploying a tool that creates compliance exposure, using customer data for model training without contractual authority, and having no record of what AI tools are running in production.

Ready to work through your AI investment decision?